Join leading experts in the Cell & Gene Therapy field as well as thought leaders in the self-insurance industry who will discuss the latest industry developments along with related implications for self-insured payers.  You will leave with detailed knowledge of the CGT pipeline, manufacturer perspective on pricing, value-based pricing consideration, potential financial mitigation/risk strategies, plan document guidance, and more.

Please note that limited seating is available, and this program will sell out.

Wednesday, May 29, 2024

3:00 p.m. to 6:30 p.m.

Registration Open

5:00 p.m. to 6:30 p.m.

Welcome Reception

Thursday, May 30, 2024

7:00 a.m. to 8:00 a.m.

Continental Breakfast

8:00 a.m. to 8:15 a.m.

Welcome & SIIA Cell & Gene Therapy Task Force Update


Shaun Peterson
SIIA Cell & Gene Task Force 

8:15 a.m. to 9:30 a.m.

The Manufacturers' Perspective


Mark Trusheim (Invited)
Strategic Director


Jay Newman
SVP & Head of Commercial Development, 
Pricing & Reimbursement
Spark Therapeutics, Inc

LeeAnna Hoskins
VP Payer Access & Reimbursement
Sarepta Therapeutics  

Susan Serrano
Senior Director, Contracting and Payer Marketing
bluebird bio 

9:30 a.m. - 10:45 a.m.

Marketplace Solutions for Self-Insured Payers – What’s Working?

Like it has done when faced with past challenges, the self-insurance industry is adapting to evolving CGT realities, with companies bringing new solutions to market and working to develop additional solutions for future introduction. Without advertising specific company products/services, this session will discuss the type of market solutions available to self-insured payers today, what may be coming soon, the gaps that have yet to be addressed, as well as the challenges that are still out there.


Richard Fleder
ELMCRx Solutions


Ashley Hull
Executive Vice President

Brooks Wildasin
Co-Founder & Chief Underwriting Officer
OutcomeRx  Insurance Management Services, LLC.

Chris Ford 
Chief Innovation Officer

Joe Sabol
Senior Vice President
DW Van Dyke

10:45 a.m. - 11:00 a.m.


11:00 a.m. – Noon

Approval Pathways and Effects on Coverage

With the acceleration of approved treatments, self-insured employers must now make more CGT coverage decisions at a faster pace. This session will address how and why accelerated approval pathways exist and how that impacts medical policy and key coverage decision considerations.


Rachael Anatol
Deputy Super Office Director
Food & Drug Administration
Office of Therapeutic Products

Noon to 1:00 p.m.

Hosted Lunch

1:00 p.m. to 1:45 p.m.

One Patient’s Story with Cell & Gene Therapy Treatment

While there are certainly many important business, regulatory, and clinical CGT details that warrant ongoing discussion, the patient is at the center of all the stakeholders in the room. This session will put an actual face and voice to how CGT treatment can change lives. Our speakers will address the excitement and challenges this community faces in light of the new approved therapies.


Rae Blaylark
President & CEO
Sickle Cell Foundation of Minnesota 

1:45 p.m. – 3:00 p.m.

CGT & Financial Risk Transfer Considerations

Given the large price tags associated with many CGTs, the self-insurance industry Is grappling with various financial risk transfer strategies to enable employers to cover important new treatments. This panel will discuss what is happening now in the marketplace and where the thought leaders see things going. Perspectives include stop-loss, MGU, reinsurance, and captive insurance.


Raj Gulati 
Senior Vice President
Risk Strategies 


Theresa Galizia
Berkley Accident & Risk

Mike Remeika
Skyward Accident & Health

Paul Valentini
Senior Vice President
Tatum Re

Mehb Khoja
Chief Actuary
BCS Financial Corporation

3:15 p.m. - 4:15 p.m.

Understanding the Provider Perspective

As new therapies receive approval, physicians and facilities face several challenges that may affect patient access, including administrative policies from payers, payment policy issues, and regulatory obstacles. Furthermore, physicians are committed to offering lifesaving care despite these challenges while also addressing concerns about sustainability. This panel will discuss the various issues that physicians and healthcare facilities encounter as they strive to deliver patient-centered care without incurring substantial receivables or facing uncertainties regarding payment.


Stephanie Farnia
Nimitt Consulting 


Claire White, MSN, RN
Policy Analyst
Children’s Hospital of Philadelphia 
Cellular Therapy & Transplant Section

Stephan Grupp, MD
Program Director
Children’s Hospital of Philadelphia 
Cellular Therapy & Transplant Section

Amy Emmert, MScPH 
Executive Director, External Affairs
HSCT & Cellular Therapy Service Line
Dana-Farber Cancer Institute

4:15 p.m. - 5:00 p.m.

Share, Ask & Answer

We’ve reserved the last hour of the program for a moderated group discussion where attendees will be encouraged to engage with each other regarding what they have heard during the day of presentations and related conversations.


Ashley Hume
Chief Commercial Officer
Emerging Therapy Solutions 

5:00 p.m.

Forum Concludes

5:00 p.m.- 6:00 p.m.

Closing Reception

P.O. Box 1237, Simpsonville, SC 29681 | p: 800.851.7789 | Contact Us
2024 Self-Insurance Institute of America, Inc.